


80XSELL
SECTOR 4
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents,
Attn: Box Missing Parts,
Washington, D.C. 20231, on 9-8-99

PATENT
Attorney Docket No. 16303-007510



TOWNSEND and TOWNSEND and CREW LLP
By Linda Shaffer

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

PHALGUN B. JOSHI, *et al.*

Application No.: 09/295,925

Filed: April 21, 1999

For: COMBINATION THERAPY USING
NUCLEIC ACIDS AND RADIO THERAPY

Examiner: Unassigned

Art Unit: 1636

TRANSMITTAL LETTER - RESPONSE
TO NOTICE OF MISSING PARTS

Attn: Box Missing Parts
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Pursuant to the Notice to File Missing Parts of Application - Filing Date Granted dated May 20, 1999, enclosed are the following to be made of record in the above-identified application:


- 1) Petition to Extend Time
- 2) Communication Under 37 C.F.R. §§ 1.821-1.825 and Preliminary Amendment w/paper copy and diskette containing sequence listing
- 3) Executed Declaration and Power of Attorney (two separate)
- 4) Verified Statement Claiming Small Entity Status of British Columbia Cancer Agency
- 5) Verified Statement Claiming Small Entity Status of Inex Pharmaceuticals Corporation
- 6) Copy of Notice of Missing Parts
- 7) Copy of Notice to Comply

Please charge Deposit Account No. 20-1430 for the following fees:

Small entity:	(a) Filing Fee (§ 1.16(a)) (Small Entity)	\$ 380.00
	(b) Excess Claims Fees (§ 1.16(b), (c)):	
	45 - 20 = 25 x \$ 9 =	\$225.00
	3 - 3 = 0 x \$ 39 =	\$0.00
	(c) Missing Parts Surcharge	\$65.00
	TOTAL FEES TO BE CHARGED	\$670.00


The Commissioner is hereby authorized to charge any additional fees associated with this paper or during the pendency of this application, or credit any overpayment, to Deposit Account No. 20-1430. This Transmittal Letter is submitted in triplicate.

Respectfully submitted,


Eugenia Garrett Wackowski
Reg. No. 37,380

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
(415) 576-0200
Fax (415) 576-0300
EGW/lls

SF 1025125 v1



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARK
Washington, D.C. 20231

#4

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO./TITLE
09/295,925	04/21/99	JOSHI	P 16303-007510

0242/0520

EUGENIA GARRETT WACKOWSKI
TOWNSEND AND TOWNSEND AND CREW
TWO EMBARCADERO CENTER 8TH FLOOR
SAN FRANCISCO CA 94111-3834

NOT ASSIGNED

1636

DATE MAILED:

05/20/99

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

1. This application fails to comply with the requirements of 37 CFR 1.821-1.825.

2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).

3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).

4. A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."

5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).

6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).

7. OTHER: _____

APPLICANT MUST PROVIDE:

An initial or substitute computer readable form (CRF) copy of the "Sequence Listing."

An initial or substitute paper copy of the "Sequence Listing," as well as an amendment directing its entry into the specification.

A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE CONTACT:

For Rules Interpretation, call (703) 308-1123.

For CRF submission help, call (703) 308-4212.

For PatentIn software help, call (703) 308-6856.

T-1 Fwd
Customer Service Center
Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

